CANTON STRATEGIC HOLDINGS IN
CNTNNASDAQTrading Snapshot
- Day Range
- $1.87 – $1.91
- 52-Week Range
- $1.08 – $9.08
- Volume
- $5.02B
- Avg Volume
- $5.90B
- Shares Outstanding
- 77.1M
- Next Earnings
- Oct 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $3M
- P/E Ratio
- -0.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.39
- Dividend Yield
- 0.00%
Why Investors Own CNTN
- ✓High-growth profile — revenue up +39.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 29% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CANTON STRATEGIC HOLDINGS IN
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Canton Strategic: Highly Intriguing Blockchain Treasury With Tangible Risks
Canton Strategic Holdings pivots from biotech to a blockchain treasury focused on Canton Coin and Super Validators. Click for more information on CNTN.
Canton Strategic Holdings, Inc. Announces Sale of Gravitas Life Sciences, LLC
Canton Strategic Holdings, Inc., (NASDAQ: CNTN) ("Canton Strategic Holdings" or the "Company") the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional financial markets, today announced the sale of its biotech research and development arm, Gravitas Life Sciences, LLC ("Gravitas"), to Gravitas Collective Corp. The transaction was approved unanimously by the Board of Directors and closed on July 17, 2026.
Tharimmune Investor Update Highlights Canton Network Growth, DTCC Pilot Momentum
Canton Strategic Holdings executives said the Canton Network saw higher transaction activity, broader institutional participation and significant governance changes during the second quarter, while highlighting a DTCC tokenization pilot and a growing market for Canton Coin locking services. Speakin
Tharimmune Stockholders Elect Board, Ratify Auditor at 2026 Annual Meeting
Canton Strategic Holdings held its 2026 Annual Meeting of Stockholders virtually at 2:00 p.m. Eastern Time, with Chief Executive Officer and Chairman Mark Wendland presiding over the proceedings. Wendland said the meeting had been called by the company’s board of directors and that June 16, 2026, w